COVID-19 Vaccination Status, Attitudes, and Values among US Adults in September 2021
- PMID: 35807016
- PMCID: PMC9267733
- DOI: 10.3390/jcm11133734
COVID-19 Vaccination Status, Attitudes, and Values among US Adults in September 2021
Abstract
Background: The Delta COVID-19 variant caused a resurgence in cases and deaths during the summer of 2021, particularly among the unvaccinated, highlighting the need to increase vaccine coverage. We describe a survey conducted in September 2021, in the midst of the Delta variant surge, after the FDA fully approved Pfizer-BioNTech’s vaccine for ages 16+ and issued an emergency use authorization for ages 12−15. Methods and Findings: US adults were surveyed to measure COVID-19 vaccination status, intentions, attitudes, values, and trust in public health authorities. More than three-quarters (77%) reported receiving at least one dose of COVID-19 vaccination. Of the unvaccinated, 6% intended to vaccinate, 40% were unlikely to ever vaccinate, and 55% remained uncertain. Most of the unvaccinated were <45 years old (62%), without a bachelor’s degree (83%), earning less than $85,000 annually (74%), and Republican/Independent (66%). Concerns among the unvaccinated-yet-still-uncertain included the vaccines’ safety (86%), speed of development (86%), and suspicion of government (79%) and pharmaceutical companies (69%). Most (86%) of the unvaccinated reported they would not vaccinate if mandated by their employer. About one third (34%) of the unvaccinated reported facing at least one barrier to vaccination. Conclusion: More than half of unvaccinated adults remained uncertain about COVID-19 vaccination, indicating an opportunity to support their decision making. Public health must increase easy and equitable access to vaccination and renew efforts to provide unvaccinated populations access to information from trusted sources.
Keywords: COVID-19; vaccination; vaccine; vaccine hesitancy.
Conflict of interest statement
Matthew Dudley has received research support from Merck and Walgreens. Daniel Salmon has received consulting and/or research support from Janssen and Merck. Jennifer Gerber has received support from RTI International. Rajiv Rimal has received funding from the Vaccination Confidence Fund, which is jointly funded by Facebook and Merck. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
References
-
- FDA Takes Key Action in Fight against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine. [(accessed on 11 December 2020)]; Available online: https://www.fda.gov/news-events/press-announcements/fda-takes-key-action....
-
- FDA Takes Additional Action in Fight Against COVID-19 by Issuing Emergency Use Authorization for Second COVID-19 Vaccine. [(accessed on 18 December 2020)]; Available online: https://www.fda.gov/news-events/press-announcements/fda-takes-additional....
-
- FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine. [(accessed on 27 February 2021)]; Available online: https://www.fda.gov/news-events/press-announcements/fda-issues-emergency....
-
- Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. [(accessed on 10 May 2021)]; Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19....
-
- FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age. [(accessed on 29 October 2021)]; Available online: https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfize....
Grants and funding
LinkOut - more resources
Full Text Sources
